GlassScriptPhysician profile
Prashanth Kanagarajah
NPI 1518307941
$17,035.79
in general payments reported to CMS, 2019-2025
37 companies · $4,517 in 2025
The $4,517 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $545 · 2021: $1,844 · 2022: $2,371 · 2023: $5,989 · 2024: $1,671 · 2025: $4,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,855 · Education: $2,500 · Travel and Lodging: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,855.02 |
| Education | $2,500.00 |
| Travel and Lodging | $1,821.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,041.89 | 2022-2025 | |
| Pinnacle Biologics, INC | $3,985.24 | 2021-2023 | Photofrin |
| Glaxosmithkline, LLC. | $2,074.24 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,736.01 | 2021-2024 | Fasenra, Airsupra, Breztri |
| United Therapeutics Corporation | $604.20 | 2020-2022 | |
| Grifols USA, LLC | $500.12 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Pulmonx Corporation | $430.03 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $427.73 | 2021-2024 | Opsumit, Uptravi |
| Genzyme Corporation | $413.99 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.56 | 2020-2024 | Stiolto Respimat, Spiriva Respimat |
| Paratek Pharmaceuticals, INC. | $275.18 | 2022-2023 | Nuzyra |
| Insmed, INC. | $246.68 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $194.03 | 2021-2023 | Dupixent |
| Mylan Specialty L.P. | $149.02 | 2021-2023 | Yupelri |
| Zoll Respicardia, INC. | $139.71 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $129.53 | 2021 | |
| La Jolla Pharmaceutical Company | $128.60 | 2023 | Giapreza |
| Idorsia Pharmaceuticals US INC | $124.65 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $123.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.89 | 2021-2023 | Glassia |
| Genentech USA, INC. | $116.87 | 2019-2023 | Xolair |
| Axsome Therapeutics, INC. | $113.85 | 2024 | Sunosi |
| Harmony Biosciences LLC | $112.95 | 2021 | |
| Electromed, INC. | $109.17 | 2021-2024 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $96.38 | 2022 | |
| Vifor Pharma, INC. | $50.90 | 2024 | Zemaira |
| Ethicon INC. | $32.02 | 2021 | |
| Baxter Healthcare | $27.36 | 2024 | Hillrom - Monarch Airway Clearance System |
| Olympus America INC. | $26.10 | 2022 | |
| Merck Sharp & Dohme LLC | $20.19 | 2022 | |
| Pfizer INC. | $19.12 | 2022 | |
| Philips North America LLC | $15.77 | 2023 | |
| Fisher & Paykel Healthcare INC | $15.28 | 2022 | |
| Verona Pharma, INC. | $14.98 | 2025 | Ohtuvayre |
| Inogen, INC. | $13.69 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Kanagarajah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.